

101540359
CASE PA74-32832A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV524615550US
Express Mail Label NumberJune 23, 2005
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

23 JUN 2005

IN RE PCT NATIONAL STAGE APPLICATION OF

ALTMANN ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/14741

FILED: 22 DECEMBER 2003

U.S. APPLICATION NO: Not Yet Assigned

35 USC §371 DATE:

FOR: DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2-AMINO-PHENYL
METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID
HORMONE**MS: Amendment**Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450INFORMATION DISCLOSURE STATEMENT

Sir:


This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP03/14741, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Susan Hess
Attorney for Applicants
Reg. No. 37,350Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7859
Date: June 23, 2005

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

 10-540359
 APPLICATION NO.
 Not Yet Assigned
 APPLICANT
 ALTMANN ET AL.
 FILING DATE
 Herewith

Group

JC20 Rec'd PCT/PTO 23 JUN 2005

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	4,387,223	6/7/83	Yamamoto Michihiro et al.			
	AB	3,812,257	5/21/74	Inaha et al.			
	AC	5,773,663	6/30/98	Rehnig et al.			
	AD	5,856,503	1/5/99	Maerki et al.			
	AE	3,925,548	12/9/75	Pleffingen			
	AF	6,211,244	4/3/01	Delmar et al.			
	AG						
	AH	ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./					
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

Names

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	NO
	AM	011 812 100	7/13/79	Swiss			<input type="checkbox"/>	<input type="checkbox"/>
	AN	GB 1 253 790	5/23/74	Great Britain			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 92/24003	3/20/92	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AP	WO 92/402702	12/23/92	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

		Russell et al., "Synthesis and Renal Vasodilator Activity of Substituted 4-ethyl(aryl) 2-oxoquinazolin-1-yl Fatty Acids", European Journal of Medicinal Chemistry, Vol. 27, No. 3, pp. 277-284, (1992).					
		Database Caplus 'Online' Chemical Abstracts Service, Columbus, Ohio; XP003036950 & Miyagishi et al., "General Pharmaceutical Studies on Opiroquazone (SL-973) and its Metabolites" OTL TAKUKI, vol. 19, No. 4, pp. 9-22 (1970).					
/T.N./	AT	Masai, et al., "Carbon-13 Nuclear Magnetic Resonance Studies of Anti-Inflammatory 2(1H)-Quinazolinones", Chemical & Pharmaceutical Bulletin, Vol. 25, No. 11, pp. 3018-3022, (1977).					

EXAMINER

/Tamthom Truong/

DATE CONSIDERED

06/10/2008

*EXAMINER:

Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

Crossed out references are the ones not provided.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. BOOK
PAGE 3033A
APPLICATION NO.
Not Yet Assigned
APPLICANT
ALTMANN ET AL.
FILING DATE
HerewithSheet 1 of 1
10/5/0359

Group

JC20 Rec'd PCT/PTO 23 JUN 2005

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

DA	Database Caplus 'Online! Chemical Abstracts Service, Columbus, Ohio: XP002280289 retrieved from STN accession no. 503745 rn: 37554-38-4 & Mardente et al, "GLC-ECD Determination of 1-(2-Hydroxyethyl)-3-Hydroxy-7-Chloro-1,3-Dihydro-5-(0-Fluorophenyl)-2H-1,4-Benzodiazepin-2-one (SAS 643) in Plasma and Urine and Identification of its main Biotransformation Products" Therapeutic Drug Monitoring, Vol. 3, No. 4, pp. 351-356 (1981)
DB	Database Caplus 'Online! Chemical Abstracts Service, Columbus, Ohio: XP002280290 retrieved from STN accession no. 1142 database accession no. 1994:244939 rn: 154374-68-2P; 154374-67-1 & M. I. Maeda et al, "Synthesis of Some Novel 2(1H)-Quinazolinones and 2-Thioxoanalogs from Newly Synthesized 1-acyl-3-alkoxyphenylureas and Tioureas", Journal of Chemical Technology and Biotechnology, Vol. 58, No. 4, pp. 391-394, (1993)
DC	Database Caplus 'Online! Chemical Abstracts Service, Columbus, Ohio: XP002280291 retrieved from STN accession no. 1277 database accession no. 1981:461773 m 78350-38-6 & JP 55 143959 (Shionogi and Co.) 1980
DD	Database Crossfire Beilstein 'Online! Beilstein Institut zur Förderung der Chemischen Wissenschaften, XP002280292 Database Accession no. 6810088 & Berger et al., ACTA Crystallogr. Sect. C: Cryst. Struct. Commun, Vol. 50, pp. 773-775, (1994)
DE	
DF	
DG	
DH	
DI	
DJ	
DK	
DL	
DM	
DN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant

References are not provided.